"The three most common eye diseases – diabetic retinopathy, age-related macular degeneration, and glaucoma – can be detected far earlier with algorithmic retinal image analysis. These three diseases, however, are just the tip of the iceberg," said Prof. Mingguang He. "The eye is a window through which we can discern any disease that affects the microvascular system. This technology allows clinicians to act faster and prevent significant impacts on quality of life."
The Ascertain team's goal is to facilitate and accelerate the availability of Optain's advanced capabilities here in the U.S., benefitting both providers and patients. Northwell Health, the largest healthcare provider and private employer in New York State and one of the ten largest health systems in the U.S., will be Optain's flagship commercial customer. Optain's groundbreaking AI-enabled technology will help Northwell catalyze its mission to make healthcare more equitable and ensure more patients have access to high-quality preventive care.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"By harnessing the tremendous insight that can be gained through retinal scanning, and combining that with innovative AI, Optain's technology represents enormous potential to improve the manner and timeliness in which we can diagnose and treat disease, said Richard Braunstein, MD, Senior Vice President and Executive Director of Ophthalmology at Northwell Health. "We believe that leveraging Northwell's clinical expertise, data assets and vast clinical footprint positions us well to refine and advance such groundbreaking solutions and improve the treatment and care of patients."
This is the collaboration's first investment in an emerging AI technology originally developed overseas. One of Ascertain's goals is to expedite the pathway to regulatory approval for these innovative companies, supporting their launch and scale within the United States. By doing so, Ascertain raises awareness and accelerates the impact of solutions that might otherwise have gone unnoticed. Eyetelligence will continue to expand both in Australia and in other international markets. As the brand grows and scales, the Ascertain team is determined to foster innovation and improve patient care by investing in and cultivating solutions like those offered by Optain. They are eager to connect with other innovative founders, investors and partners in the healthcare AI space.
About Optain
Optain is transforming preventive health with industry-leading AI-enabled software and hardware products that noninvasively diagnose eye and systemic health conditions in real-time. Using the eye as a gateway to monitor whole-person health, Optain's AI-enabled portable retinal camera empowers clinicians to screen for over 140 eye and systemic conditions in the early stages of development. The company's approach is based on over a decade of research conducted by Professor Mingguang He, a leading researcher at the University of Melbourne and Centre for Eye Research in Australia. By placing powerful AI-enabled diagnostic tools in the hands of clinicians, Optain will reduce wasteful spending, close gaps in care, and make high-quality healthcare accessible to all.
Back to HCB News
